Early vs. delayed empiric antimicrobial treatment for suspected acute meningitis - a systematic review and meta-analysis

疑似急性脑膜炎早期与延迟经验性抗菌治疗的比较——系统评价和荟萃分析

阅读:1

Abstract

BACKGROUND: Acute bacterial meningitis (ABM) is a life-threatening condition requiring prompt antibiotic administration to reduce mortality and neurological sequelae. The optimal timing of empiric antimicrobial therapy remains uncertain due to limited evidence. METHODS: We conducted a systematic review following Cochrane MECIR standards. The search was carried out on the 2nd of January 2024, including studies from 1946 to January 2024. We included randomized controlled trials and prospective cohort studies with comparator arms. Two reviewers independently screened studies, extracted data, and assessed risk of bias using the ROBINS-I tool. Meta-analyses were performed using RevMan Web, and certainty of evidence was evaluated with the GRADE approach. RESULTS: Three prospective cohort studies met the inclusion criteria. Very low-certainty evidence from 3 studies with 601 participants revealed an uncertain effect of early empiric antimicrobial treatment on all-cause mortality (RR 0.41, 95% CI 0.26–0.65; I²=44.9%). In addition, very low-certainty evidence from one study with 281 participants indicated an uncertain impact of pre-hospital admission i.e., early antibiotic therapy on development of neurological sequelae, including hearing loss (RR 2.98, 95% CI 1.09–8.13) and paresis (RR 2.21, 95% CI 0.93–5.25). This study also revealed an uncertain effect on CSF (RR 0.95, 95% CI 0.90–1.01) and blood culture positivity rates (RR 0.90, 95% CI 0.80–1.01). Very low-certainty evidence from another study with 148 participants revealed an uncertain impact of early antibiotic therapy (≤ 3 h) on adverse events (RR 0.70, 95% CI 0.53–0.92). CONCLUSION: The effect of early versus delayed empiric antimicrobial treatment for suspected ABM on mortality, neurological sequelae, and CSF and blood culture positivity rates is uncertain due to very low-certainty evidence. Further high-quality studies are needed to guide clinical practice. TRIAL REGISTRATION: PROSPERO registration, CRD42024531465. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12879-026-12858-x.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。